| HIV, Drug Use, Sexual Risk | Lifetime | 76 | CN 3 | 99.42 |
| HIV/AIDS Research and Interventions | Lifetime | 249 | CN 4 | 99.29 |
| COVID-19 and healthcare impacts | Lifetime | 283 | CN 9 | 96.14 |
| Innovative Educational Techniques | Lifetime | 15 | CN 5 | 92.40 |
| Hepatitis B Virus Studies | Lifetime | 740 | CN 43 | 98.15 |
| Reproductive tract infections research | Lifetime | 255 | CN 2 | 97.81 |
| Syphilis Diagnosis and Treatment | Lifetime | 150 | CN 1 | 96.96 |
| Drug Transport and Resistance Mechanisms | Lifetime | 810 | CN 28 | 96.97 |
| Cervical Cancer and HPV Research | Lifetime | 709 | CN 16 | 97.02 |
| Higher Education and Teaching Methods | Lifetime | 145 | CN 110 | 88.37 |
| Sex work and related issues | Lifetime | 316 | CN 6 | 96.42 |
| Genital Health and Disease | Lifetime | 500 | CN 10 | 96.07 |
| Inflammatory Biomarkers in Disease Prognosis | Lifetime | 392 | CN 53 | 93.46 |
| COVID-19 Pandemic Impacts | Lifetime | 325 | CN 38 | 93.46 |
| Adolescent Sexual and Reproductive Health | Lifetime | 842 | CN 8 | 96.45 |
| COVID-19 epidemiological studies | Lifetime | 852 | CN 125 | 95.18 |
| Cardiovascular Health and Risk Factors | Lifetime | 441 | CN 39 | 94.63 |
| Salivary Gland Disorders and Functions | Lifetime | 681 | CN 15 | 93.69 |
| Hepatitis Viruses Studies and Epidemiology | Lifetime | 835 | CN 52 | 93.25 |
| COVID-19 impact on air quality | Lifetime | 965 | CN 189 | 65.70 |
| Focus Groups and Qualitative Methods | Lifetime | 846 | CN 6 | 26.55 |
| Reproductive tract infections research | 2021-2025 | 19 | CN 1 | 98.41 |
| Hepatitis B Virus Studies | 2021-2025 | 57 | CN 11 | 98.49 |
| HIV/AIDS Research and Interventions | 2021-2025 | 102 | CN 2 | 98.41 |
| COVID-19 and healthcare impacts | 2021-2025 | 208 | CN 6 | 95.93 |
| Liver Disease Diagnosis and Treatment | 2021-2025 | 543 | CN 61 | 97.57 |
| Air Quality and Health Impacts | 2021-2025 | 375 | CN 203 | 97.35 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 823 | CN 178 | 96.80 |
| Cardiovascular Health and Risk Factors | 2021-2025 | 98 | CN 15 | 95.13 |
| Cervical Cancer and HPV Research | 2021-2025 | 207 | CN 19 | 95.35 |
| HIV, Drug Use, Sexual Risk | 2021-2025 | 201 | CN 5 | 95.89 |
| Hepatitis C virus research | 2021-2025 | 258 | CN 27 | 95.75 |
| Vaccine Coverage and Hesitancy | 2021-2025 | 449 | CN 43 | 94.34 |
| Syphilis Diagnosis and Treatment | 2021-2025 | 73 | CN 3 | 93.53 |
| Sepsis Diagnosis and Treatment | 2021-2025 | 489 | CN 55 | 92.96 |
| Respiratory viral infections research | 2021-2025 | 571 | CN 47 | 91.85 |
| Colorectal and Anal Carcinomas | 2021-2025 | 362 | CN 37 | 91.26 |
| COVID-19 epidemiological studies | 2021-2025 | 913 | CN 148 | 90.72 |
| Chronic Disease Management Strategies | 2021-2025 | 485 | CN 43 | 89.38 |
| Nutritional Studies and Diet | 2021-2025 | 875 | CN 100 | 91.50 |
| Retinal Diseases and Treatments | 2021-2025 | 864 | CN 111 | 92.27 |
| Hepatocellular Carcinoma Treatment and Prognosis | 2021-2025 | 896 | CN 234 | 91.84 |
| Air Quality Monitoring and Forecasting | 2021-2025 | 557 | CN 287 | 89.35 |
| Genital Health and Disease | 2021-2025 | 263 | CN 17 | 87.31 |
| Retinal Imaging and Analysis | 2021-2025 | 741 | CN 130 | 90.24 |
| HIV Research and Treatment | 2021-2025 | 698 | CN 71 | 88.89 |
| Adolescent Sexual and Reproductive Health | 2021-2025 | 549 | CN 7 | 89.23 |
| Global Public Health Policies and Epidemiology | 2021-2025 | 432 | CN 14 | 84.86 |
| Health and Wellbeing Research | 2021-2025 | 298 | CN 27 | 82.36 |
| Blood groups and transfusion | 2021-2025 | 415 | CN 28 | 85.27 |
| Drug Transport and Resistance Mechanisms | 2021-2025 | 466 | CN 102 | 82.42 |
| Urinary Tract Infections Management | 2021-2025 | 565 | CN 24 | 82.66 |
| Global Health Care Issues | 2021-2025 | 884 | CN 133 | 78.33 |
| Healthcare Systems and Reforms | 2021-2025 | 599 | CN 81 | 82.04 |
| Effects and risks of endocrine disrupting chemicals | 2021-2025 | 927 | CN 324 | 82.17 |
| Sex work and related issues | 2021-2025 | 503 | CN 8 | 79.60 |
| Management of metastatic bone disease | 2021-2025 | 628 | CN 72 | 76.72 |
| Gastrointestinal motility and disorders | 2021-2025 | 843 | CN 132 | 78.39 |
| Microbial infections and disease research | 2021-2025 | 930 | CN 172 | 72.97 |
| Cell Adhesion Molecules Research | 2021-2025 | 869 | CN 119 | 69.73 |
| Hepatitis Viruses Studies and Epidemiology | 2021-2025 | 679 | CN 114 | 69.90 |
| Genetic Syndromes and Imprinting | 2021-2025 | 823 | CN 81 | 63.39 |
| Poxvirus research and outbreaks | 2021-2025 | 966 | CN 89 | 63.96 |
| Educational Reforms and Innovations | 2021-2025 | 305 | CN 182 | 61.88 |
| Nitric Oxide and Endothelin Effects | 2021-2025 | 717 | CN 168 | 58.79 |
| Blood donation and transfusion practices | 2021-2025 | 800 | CN 25 | 57.81 |
| Regional Development and Environment | 2021-2025 | 161 | CN 127 | 56.26 |
| Natural Compounds in Disease Treatment | 2021-2025 | 162 | CN 135 | 52.31 |
| Pericarditis and Cardiac Tamponade | 2021-2025 | 979 | CN 31 | 43.94 |
| Female Genital Mutilation/Cutting Issues | 2021-2025 | 572 | CN 50 | 43.25 |
| HIV, TB, and STIs Epidemiology | 2021-2025 | 123 | CN 5 | 38.60 |